Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.

Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P.

J Am Coll Cardiol. 2005 Apr 19;45(8):1295-301. Review.

2.

Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease.

Patrignani P.

Thromb Res. 2003 Jun 15;110(5-6):281-6. Review.

PMID:
14592549
3.

Clinical pharmacology of platelet cyclooxygenase inhibition.

Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davì G, Forni L.

Circulation. 1985 Dec;72(6):1177-84. Review.

PMID:
3933848
4.

Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction.

de Gaetano G, Cerletti C, Dejana E, Latini R.

Circulation. 1985 Dec;72(6):1185-93. Review.

PMID:
2998640
5.

Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection.

Gaziano JM, Gibson CM.

Am J Cardiol. 2006 May 8;97(9A):23-9. Epub 2006 Mar 30. Review.

PMID:
16675319
6.

[Aspirin resistance].

Miyata S, Miyata T, Kada A, Nagatsuka K.

Brain Nerve. 2008 Nov;60(11):1357-64. Review. Japanese.

PMID:
19069170
7.

Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin.

Corman SL, Fedutes BA, Ansani NT.

Ann Pharmacother. 2005 Jun;39(6):1073-9. Epub 2005 May 3. Review.

PMID:
15870140
8.

[Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].

Flipo RM.

Presse Med. 2006 Sep;35(9 Spec No 1):1S53-60. Review. French.

PMID:
17078596
9.

Effects of non-steroidal anti-inflammatory drugs on the in vivo synthesis of thromboxane and prostacyclin in humans.

Drvota V, Vesterqvist O, Gréen K.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:153-6. Review.

PMID:
1825533
10.

Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects.

Catella-Lawson F.

Neurology. 2001;57(5 Suppl 2):S5-7. Review.

PMID:
11552047
11.

Cardiovascular hazard and non-steroidal anti-inflammatory drugs.

Wang D, Wang M, Cheng Y, Fitzgerald GA.

Curr Opin Pharmacol. 2005 Apr;5(2):204-10. Review. Erratum in: Curr Opin Pharmacol. 2005 Oct;5(5):556. Wong, Dairong [corrected to Wang, Dairong].

PMID:
15780832
12.

[Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism].

Hillarp A.

Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. Review. Swedish.

PMID:
15575422
13.

Aspirin resistance.

Hankey GJ, Eikelboom JW.

Lancet. 2006 Feb 18;367(9510):606-17. Review.

PMID:
16488805
14.

Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects.

Stepensky D, Rimon G.

Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):41-52. doi: 10.1517/17425255.2014.971010. Epub 2014 Oct 13. Review.

PMID:
25307725
15.

The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin.

Patrono C.

J Am Coll Cardiol. 2015 Jul 7;66(1):74-85. doi: 10.1016/j.jacc.2015.05.012. Review.

16.

Aspirin: a pharmacologic profile.

Malseed RT, Malseed ZK.

Am J Pharm Sci Support Public Health. 1978 Jul-Aug;150(4):99-106. Review. No abstract available.

PMID:
362948
17.

Aspirin resistance: definition, mechanisms and clinical read-outs.

Patrono C.

J Thromb Haemost. 2003 Aug;1(8):1710-3. Review. No abstract available.

18.

Molecular targets of aspirin and cancer prevention.

Alfonso L, Ai G, Spitale RC, Bhat GJ.

Br J Cancer. 2014 Jul 8;111(1):61-7. doi: 10.1038/bjc.2014.271. Epub 2014 May 29. Review.

Supplemental Content

Support Center